Drug Discovery & Molecular Design - software & AI news

Daily news on software, AI, and companies shaping drug discovery & molecular design.

Showing 229 results
A minimalist representation of a drug compound molecule in flat design.

Jun 3, 2026

Recursion vs. Schrodinger: Comparing Biotech and Software Drug Discovery Strategies in 2026 - News and Statistics

The competition between Recursion Pharmaceuticals and Schrodinger highlights distinct drug discovery strategies as they leverage technology and data in their operations.Recursion Pharmaceuticals focuses on mechanizing drug discovery through artificial intelligence and extensive data analysis within the biotech sector. The company collaborates with major industry players like Roche and Bayer, relying heavily on their partnerships for revenue. Despite reporting a revenue increase of 26.9% to appro
A supercomputer in a research lab with NVIDIA GPUs

Jun 2, 2026

Scientific Infrastructure or Expensive Theatre? AI Discovery’s Reckoning in Asia

The integration of artificial intelligence (AI) within the pharmaceutical industry is rapidly evolving, yet the gap between investment and tangible outcomes remains significant, particularly in Asia.Recent developments highlight the growing conviction that AI is essential infrastructure in drug research and development. For instance, Eli Lilly's launch of the "LillyPod," a supercomputer equipped with over 1,000 NVIDIA GPUs, symbolizes this trend. However, despite such advancements, the company a
A minimalist illustration of a pill and tablet on a solid background.

Jun 2, 2026

BullFrog AI Announces New Commercial Leadership Team to Execute Growth Strategy for its Integrated Pharma AI Platform

BullFrog AI has announced the formation of a new commercial leadership team aimed at accelerating growth for its integrated pharmaceutical AI platform.The newly appointed team consists of seasoned executives with extensive backgrounds in enterprise IT solutions, drug discovery, and advanced therapy platforms. Their collective expertise is expected to enhance BullFrog AI's commercial strategy and expand its pipeline for AI-driven solutions, including products like bfPREP, bfLEAP, and bfARENAS. Th
A glass vial filled with liquid on a lab bench in a dimly lit laboratory.

Jun 2, 2026

Veteran tech and biotech execs join BullFrog AI to push drug discovery

BullFrog AI has announced the formation of a new commercial leadership team aimed at driving growth for its AI-driven drug discovery platform.The company, based in Gaithersburg, Maryland, is leveraging the expertise of seasoned executives to enhance its commercial strategy and expand its market presence. The newly appointed leaders include John Stewart as SVP of Commercial Sales, Eric Roos as SVP of Business Development & Corporate Strategy, and Tom Hazel, Ph.D., as VP of Scientific Operations.
A minimalist representation of a drug compound and AI integration in biotech.

Jun 2, 2026

Rakovina’s Rx: AI and Austerity Fuel a Biotech Turnaround

Rakovina Therapeutics has successfully navigated a financial turnaround by integrating AI into its drug discovery process while implementing stringent cost controls.In its recent financial report for Q1 2026, Rakovina Therapeutics showcased a notable strategic shift, merging financial austerity with a robust investment in AI-driven drug discovery. This pivot has stabilized the company, improving its balance sheet and operational efficiency. The firm reported a 23% reduction in net loss, alongsid
A test tube in a laboratory setting

Jun 1, 2026

Q1 2026: When Pharma AI Partnerships Crossed a Threshold

The first quarter of 2026 marked a pivotal moment for artificial intelligence in the pharmaceutical sector, characterized not just by an increase in partnerships, but by a fundamental shift in how these collaborations are structured and integrated into the industry.In Q1 2026, the number of significant AI partnerships doubled to thirty-six compared to the same period in 2025. However, the real significance lies in the nature of these deals. They reflect a transition from experimental pilot proje
A close-up of a cell culture dish in a lab setting, with a pipette above it.

May 28, 2026

Pamela Carroll ’85 uses AI in biotechnology to tackle formerly “undruggable” drivers of disease

Pamela Carroll, a 1985 graduate of Saint Michael’s College, is pioneering the integration of artificial intelligence (AI) in biotechnology, focusing on previously "undruggable" disease drivers. Her career trajectory, which includes significant roles in both research and business, highlights the transformative potential of AI in drug discovery and development.Carroll's journey began at the National Cancer Institute, where her fascination with cell biology took root. This interest propelled her th
A test tube with protein solution in a dimly lit lab

May 28, 2026

Sino Biological's Cell-Free Protein Synthesis Supports Tencent AI for Life Sciences Lab's Protein Design Study Published in Nature Communications

Sino Biological's innovative cell-free protein synthesis technology has been pivotal in a recent study conducted by Tencent AI for Life Sciences Lab, as published in *Nature Communications*. This collaboration highlights the integration of AI in protein design, enabling the rapid validation of proteins that exhibit enhanced activity, stability, and multifunctionality.The study addresses a significant challenge in protein engineering: the transition from AI-generated amino acid sequences to funct
Molecular model on a lab table with a research notebook

May 28, 2026

Hoffman Predicts AI-Driven Drug Discovery Bonanza

Reid Hoffman, co-founder of LinkedIn and Manas AI, recently highlighted the transformative potential of AI in drug discovery during an appearance on "The Possible Podcast." He emphasized that the market for AI-driven drug discovery could surpass that of current AI chatbot applications.Hoffman pointed out that the existing chatbot market, dominated by companies like OpenAI and Anthropic, is significant, but the opportunities in drug discovery are even greater. He noted that AI technologies can si
A minimalist representation of a drug capsule and heart symbol in a dark palette.

May 28, 2026

AI-Designed Drug Enters Phase I Trial

Quotient Sciences has launched a Phase I clinical trial for a novel drug product, developed using artificial intelligence (AI), marking a potential breakthrough in AI-driven drug formulation.The trial, conducted at Quotient Sciences' UK facility, has received approval from the MHRA and aims to assess the safety and pharmacokinetics of the drug in healthy volunteers. This initiative is significant as it seeks to validate AI's role in drug development, potentially enhancing formulation design and
A minimalist illustration of a pill bottle representing non-opioid pain therapy.

May 28, 2026

Redwood AI Bridges Markets and Medicine with DTC Eligibility and Pharma Partnership

Redwood AI is making significant strides in the life sciences sector by securing DTC eligibility for US trading and partnering with Resilience Biosciences to develop non-opioid pain therapies.This week, Redwood AI has advanced its dual growth strategy, marking its entry into life sciences through a collaboration with Resilience Biosciences. The partnership aims to tackle the pressing issue of finding alternatives to opioid pain management. Utilizing its advanced computational chemistry platform,
A non-opioid therapeutic compound in a laboratory setting

May 28, 2026

Redwood AI Moves on Two Fronts: US Trading Clearance and Pharma Partnership to Drive Commercial Mome

Redwood AI is making significant strides in both market accessibility and pharmaceutical collaboration, aiming to enhance its commercial potential.The company has recently achieved DTC eligibility for its shares, facilitating easier trading for US investors. This move is designed to improve liquidity and trading efficiency, addressing previous challenges associated with manual processes in the OTCQB market. Alongside this, Redwood AI has formed a partnership with Resilience Biosciences to develo